RIGL — Rigel Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $882.62m
- $826.53m
- $294.28m
Brief: Rigel Reports Fourth Quarter And Full Year 2022 Financial Results
Rigel Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Rigel Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview
Brief: Rigel Announces Publication Of Rezlidhia Mid-Stage Clinical Results In Blood Advances
Brief: National Comprehensive Cancer Network Adds Newly Approved REZLIDHIA (Olutasidenib) To Clinical Practice Guidelines In Oncology
Brief: Rigel Pharmaceuticals Provides Business Update
Rigel Pharma rises after U.S. launch of blood cancer drug
Brief: Rigel Announces Availability Of Rezlidhia™ (Olutasidenib) In The U.S. For The Treatment Of Adult Patients With Relapsed Or Refractory Acute Myeloid Leukemia With A Susceptible Idh1 Mutation
Brief: Rigel Doses First Patient In Phase 1B Study Of R289 For The Treatment Of Lower-Risk Myelodysplastic Syndromes
U.S. STOCKS ON THE MOVE-Aurora, Boeing, Lockheed Martin
U.S. STOCKS ON THE MOVE-Warner Bros Discovery, Blackstone, Ford
U.S. STOCKS ON THE MOVE-Rigel Pharma, UiPath Inc
Rigel Pharma surges after FDA approves leukemia treatment
U.S. RESEARCH ROUNDUP- Asana, Doordash, Nayax
U.S. FDA approves Rigel Pharma's treatment for a type of leukemia (updated)
Brief: Rigel Announces U.S. FDA Approval Of Acute Myeloid Leukemia Drug Rezlidhia™ (Olutasidenib)
U.S. FDA approves Rigel Pharma's leukemia treatment
Brief: Rigel Pharmaceuticals Has Received Deficiency Letter From Listing Qualifications Department Of Nasdaq
U.S. STOCKS ON THE MOVE-Silver miners, Luxury brands, TransMedics Group